Reprogramming of amino acid metabolism in breast cancer.

Breast cancer is one of the most prevalent malignant tumours, representing a significant health risk for women. Subtyping of breast cancer is based on gene expression profiles, with five distinct subtypes identified Luminal A, Luminal B, HER2-positive, basal-like and normal-like. The heterogeneity of breast cancer represents a significant challenge to its treatment, while drug resistance limits the effectiveness of existing therapies. There is widespread amino acid metabolic reprogramming in breast cancer, and the altered amino acid metabolism observed in breast cancer cells exhibits a heterogeneous metabolic phenotype that differs from normal cells. Consequently, targeting the metabolic differences between breast and normal cells may represent a promising novel anti-cancer strategy. In this article, we review the alterations in the metabolism of amino acids such as glutamine, cystine, serine, glycine, tryptophan and arginine in breast cancer and explore the specific mechanisms by which the aberrant expression of various amino acid metabolism-related enzymes leads to alterations in the proliferative, invasive and metastatic capacities of cancer cells. Finally, we summarise the drugs targeting amino acid metabolism in breast cancer that are currently in preclinical and clinical trials, providing a theoretical basis for targeted therapy of amino acid metabolism.

• Publication year

  2025

• Venue

  Biochimica et biophysica acta. Reviews on cancer

• Publication date

  2025-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bbcan.2025.189412PMID 40780461
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The oncoprotein SET promotes serine-derived one-carbon metabolism by regulating SHMT2 enzymatic activity

  2025cited by this paper
• Global cancer statistics 2022

  2024cited by this paper
• First person profile: Quynh‐Thu Le, MD

  2024cited by this paper
• Spatial transcriptomics in breast cancer: providing insight into tumor heterogeneity and promoting individualized therapy

  2024cited by this paper
• HuR controls glutaminase RNA metabolism

  2024cited by this paper
• E-cadherin Induces Serine Synthesis to Support Progression and Metastasis of Breast Cancer.

  2024cited by this paper
• Amino acid metabolic reprogramming in the tumor microenvironment and its implication for cancer therapy

  2024cited by this paper
• Advances in spatial transcriptomics and its applications in cancer research

  2024cited by this paper
• The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolism

  2024cited by this paper
• ASS1 inhibits triple-negative breast cancer by regulating PHGDH stability and de novo serine synthesis

  2024cited by this paper
• Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation

  2024cited by this paper
• ABCG2 and SLC1A5 functionally interact to rewire metabolism and confer a survival advantage to cancer cells under oxidative stress

  2024cited by this paper
• NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells

  2024cited by this paper
• PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer

  2024cited by this paper
• The extracellular matrix supports breast cancer cell growth under amino acid starvation by promoting tyrosine catabolism

  2024cited by this paper
• Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer

  2024cited by this paper
• PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma

  2023cited by this paper
• Spatial Biology of Breast Cancer.

  2023cited by this paper
• The amino acid transporter SLC7A11 expression in breast cancer

  2023cited by this paper
• IDO-1 impairs antitumor immunity of natural killer cells in triple-negative breast cancer via up-regulation of HLA-G

  2023cited by this paper
• Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models

  2023cited by this paper
• Glutaminase (GLS1) gene expression in primary breast cancer

  2023cited by this paper
• Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer

  2023cited by this paper
• Emerging therapies in cancer metabolism.

  2023cited by this paper
• Spatial metabolomics principles and application to cancer research.

  2023cited by this paper
• IFNγ-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy.

  2023cited by this paper
• PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.

  2023cited by this paper
• Neddylation inhibition induces glutamine uptake and metabolism by targeting CRL3SPOP E3 ligase in cancer cells

  2022cited by this paper
• Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics

  2022cited by this paper
• Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions

  2022cited by this paper
• Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer

  2022cited by this paper
• Glutamine addiction promotes glucose oxidation in triple-negative breast cancer

  2022cited by this paper
• PHGDH heterogeneity potentiates cancer cell dissemination and metastasis

  2022cited by this paper
• Polarity protein SCRIB interacts with SLC3A2 to regulate proliferation and tamoxifen resistance in ER+ breast cancer

  2022cited by this paper
• Stabilization of Notch1 and β-catenin in response to ER- breast cancer-specific up-regulation of PSAT1 mediates distant metastasis

  2022cited by this paper
• Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation

  2021cited by this paper
• A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer

  2021cited by this paper
• The alternative activity of nuclear PHGDH contributes to tumour growth under nutrient stress

  2021cited by this paper
• Breast cancer derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment.

  2021cited by this paper
• Glucose and Amino Acid Metabolic Dependencies Linked to Stemness and Metastasis in Different Aggressive Cancer Types

  2021cited by this paper
• Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer.

  2021cited by this paper
• Disruption of the TCA cycle reveals an ATF4-dependent integration of redox and amino acid metabolism

  2021cited by this paper
• Trafficking to the Cell Surface of Amino Acid Transporter SLC6A14 Upregulated in Cancer Is Controlled by Phosphorylation of SEC24C Protein by AKT Kinase

  2021cited by this paper
• SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer

  2021cited by this paper
• SLC7A5 serves as a prognostic factor of breast cancer and promotes cell proliferation through activating AKT/mTORC1 signaling pathway

  2021cited by this paper
• Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer

  2021cited by this paper
• PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

  2021cited by this paper
• A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer

  2021cited by this paper
• Prognostic significance of phosphoglycerate dehydrogenase in breast cancer

  2021cited by this paper
• Indicators of L-arginine metabolism in saliva: a focus on breast cancer.

  2021cited by this paper
• Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer.

  2020cited by this paper
• Tryptophan Metabolism as a Pharmacological Target.

  2020cited by this paper
• Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression

  2020cited by this paper
• Boronic acid-based arginase inhibitors in cancer immunotherapy.

  2020cited by this paper
• Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.

  2020cited by this paper
• Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors

  2020cited by this paper
• Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer

  2020cited by this paper
• Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis–Addicted Breast Tumor Growth

  2020cited by this paper
• Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression.

  2020cited by this paper
• Comprehensive Analysis of the Expressionand Prognosis for TDO2 in Breast Cancer

  2020cited by this paper
• Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer

  2020cited by this paper
• Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics

  2020cited by this paper
• Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer.

  2020cited by this paper
• G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer

  2020cited by this paper
• SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis

  2019cited by this paper
• Glutamine Addiction and Therapeutic Strategies in Lung Cancer

  2019cited by this paper
• Mapping Metabolic Events in the Cancer Cell Cycle Reveals Arginine Catabolism in the Committed SG2M Phase.

  2019cited by this paper
• Azacoccone E inhibits cancer cell growth by targeting 3-phosphoglycerate dehydrogenase.

  2019cited by this paper
• Deprivation of glutamine in cell culture reveals its potential for treating cancer

  2019cited by this paper
• Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.

  2019cited by this paper
• LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer

  2019cited by this paper
• HPD overexpression predicts poor prognosis in breast cancer.

  2019cited by this paper
• 4-hydroxyphenylpyruvate dioxygenase promotes lung cancer growth via pentose phosphate pathway (PPP) flux mediated by LKB1-AMPK/HDAC10/G6PD axis

  2019cited by this paper
• Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor

  2019cited by this paper
• BCAA catabolism in brown fat controls energy homeostasis through SLC25A44

  2019cited by this paper
• GLS2 is protumorigenic in breast cancers

  2019cited by this paper
• Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer

  2019cited by this paper
• Selective loss of phosphoserine aminotransferase 1 (PSAT1) suppresses migration, invasion, and experimental metastasis in triple negative breast cancer

  2019cited by this paper
• The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours

  2018cited by this paper
• Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways

  2018cited by this paper
• Glutaminase isoenzymes in the metabolic therapy of cancer.

  2018cited by this paper
• N-terminal phosphorylation of glutaminase C decreases its enzymatic activity and cancer cell migration.

  2018cited by this paper
• Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.

  2018cited by this paper
• The Human SLC1A5 (ASCT2) Amino Acid Transporter: From Function to Structure and Role in Cell Biology

  2018cited by this paper
• xCT inhibition sensitizes tumors to γ-radiation via glutathione reduction

  2018cited by this paper
• IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1

  2018cited by this paper
• A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.

  2017cited by this paper
• Targeting amino acid metabolism for cancer therapy.

  2017cited by this paper
• Deciphering metabolic rewiring in breast cancer subtypes

  2017cited by this paper
• Classification Systems of Secondary Active Transporters.

  2017cited by this paper
• Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth

  2017cited by this paper
• Pharmacological Blockade of ASCT2-dependent Glutamine Transport Leads To Anti-tumor Efficacy in Preclinical Models

  2017cited by this paper
• Transcriptional hallmarks of cancer cell lines reveal an emerging role of branched chain amino acid catabolism

  2017cited by this paper
• Rational Design of Selective Allosteric Inhibitors of PHGDH and Serine Synthesis with Anti-tumor Activity.

  2017cited by this paper
• Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers

  2017cited by this paper
• The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer

  2017cited by this paper
• Branched-chain amino acid metabolism in cancer

  2017cited by this paper
• MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer

  2017cited by this paper
• PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling pathway in ER-negative breast cancer

  2017cited by this paper
• Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects

  2017cited by this paper

• No citing papers are available for this paper.